Caffeic acid-3-O-sulfate | 151481-52-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: Caffeic acid-3-O-sulfate
• 英文别名: caffeic acid 3'-O-sulfate；caffeic acid-3'-sulfate；Caffeic acid 3-sulfate；(E)-3-(4-hydroxy-3-sulfooxyphenyl)prop-2-enoic acid
• CAS: 151481-52-6
• 化学式: C₉H₈O₇S
• 分子量: 260.224
• InChiKey: VWQNTRNACRFUCQ-DUXPYHPUSA-N

物化性质

• 密度：
  1.740±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  130
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  TRANS-咖啡酸 在 氯磺酸 作用下， 以 吡啶 为溶剂， 生成 Caffeic acid-3-O-sulfate
  参考文献：
  名称：

  The antifouling activity of natural and synthetic phenol acid sulphate esters

  摘要：

  p-(sulphooxy) Cinnamic acid was isolated as a natural product for the first time from the seagrass Zostera marina (eelgrass) and was found to prevent attachment of marine bacteria and barnacles to artificial surfaces at non-toxic concentrations. Analogous synthetic sulphate esters had similar antifouling properties, while the non-sulphated phenolic acid precursors were ineffective. The antifouling properties of phenolic acid sulphates are consistent with an emerging pattern of biological activity exhibited by other sulphate esters isolated from a variety of marine organisms, and their low toxicity offers promise for the development of environmentally benign antifouling agents to protect structures in aquatic environments.

  DOI：

  10.1016/0031-9422(93)80017-m

文献信息

• Glycan therapeutics and related methods thereof
  申请人：KALEIDO BIOSCIENCES, INC.

  公开号：US10314853B2

  公开（公告）日：2019-06-11

  Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

  本发明提供了可选择包含微量营养素、多酚、益生元、益生菌或其他制剂的聚糖疗法制剂、药物组合物及其医用食品，以及制造方法。还提供了使用所述糖治疗剂的方法，例如用于调节人类胃肠道微生物群和治疗菌群失调。
• Glycan therapeutics and method of treating conditions associated with TMAO
  申请人：Kaleido Biosciences, Inc.

  公开号：US11229660B2

  公开（公告）日：2022-01-25

  Preparations of glycan therapeutics, pharmaceutical compositions and medical foods thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of human gastrointestinal microbiota and to treat dysbioses.

  本发明提供了可选择包含微量营养素、多酚、益生元、益生菌或其他制剂的聚糖疗法制剂、药物组合物及其医用食品，以及制造方法。还提供了使用所述糖治疗剂的方法，例如用于调节人类胃肠道微生物群和治疗菌群失调。
• GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF
  申请人：Kaleido Biosciences, Inc.

  公开号：EP3071235A1

  公开（公告）日：2016-09-28
• GLYCAN COMPOSITIONS AND USES THEREOF
  申请人：Kaleido Biosciences, Inc.

  公开号：EP3334437A1

  公开（公告）日：2018-06-20
• APPARATUS AND METHOD FOR PERSONALIZING NUTRITION BASED ON BIOSENSOR DATA
  申请人：Bender Tech, LLC

  公开号：US20190293627A1

  公开（公告）日：2019-09-26

  The presently disclosed subject matter is directed to a system and method of using electrochemical spectroscopy to detect and quantify concentrations of biomarkers of dietary intake and physiological health in urine samples. This presently disclosed subject matter can be used to quantify nutrition and disease biomarkers, detect dietary deficiencies, and/or report the levels back to the user. In some embodiments, the disclosed system and method can be expanded to multiplexed systems used for a wide variety of dietary nutrient biomarkers to direct diet and/or create custom therapies.